InvesTrend Does Advectus News ReleaseGo to https://www.investrend.com/
and you'll find this...
Advectus (AVX) Rated ‘Speculative Buy,’ Present Value Estimated at $388m
FinancialWire
October 29, 2002. (Institutional Report by James P.W. Darcel, CFA). Advectus Life Sciences, Inc. (OTC: AVXSF, TSX Venture: AVX, Berlin: WKN 693000) is rated a “Speculative Buy”.
Based on the research and analysis below, it is my opinion that Advectus’ Nanocure™ project for malignant brain cancer therapy using nanotechnology has an estimated present value of $388 million, based on US market demand only and terminal sales in 2018.
Advectus’ primary asset is a valuable license to commercialize a new technology platform, Nanocure ™ for the treatment of brain tumors. Based on my opinion that Nanocure™ will become a unique, new treatment for malignant brain tumors, and subject to the scientific risk factors in the report and sufficient financing, I am confident that Advectus’ success will benefit both investors and brain cancer patients around the world within a few years.
The current formulation is based on a single U.S. Food and Drug Administration (”FDA”) approved chemotherapy drug, doxorubicin (“DOX”). DOX is a potent FDA approved anti-cancer compound prescribed to treat many malignant cancers.
Presently, Advectus affiliated researchers are testing Nanocure™ technology with other chemotherapy drugs. If successful, this will greatly expand the utility and effectiveness of Advectus’ Nanocure™ brain tumor treatment platform. Nanocure™ has been shown to effectively deliver neuroactive peptides into animal neurological tissue.